Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Samuel S. Allemann"'
Pharmacogenotyping disproves genetic cause of drug-related problems in family history: a case report
Autor:
Anna Bollinger, Kurt E. Hersberger, Henriette E. Meyer zu Schwabedissen, Samuel S. Allemann, Céline K. Stäuble
Publikováno v:
BMC Anesthesiology, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background In clinical practice, family medication history is not routinely assessed as part of a patient’s family health history (FHH). The information is self-reported and can depend on the individual’s subjective perception. To illust
Externí odkaz:
https://doaj.org/article/1a032686ae7f4dfaa6a0325462f0e8cb
Publikováno v:
BMC Health Services Research, Vol 23, Iss 1, Pp 1-12 (2023)
Abstract Background Knowledge, attitudes and substitution laws of biosimilars are not consistent across countries. Biosimilar acceptance among patients and healthcare professionals may be suffering from gaps in knowledge and understanding about biosi
Externí odkaz:
https://doaj.org/article/6772672e6c8641d699dcfd51e37bee2e
Autor:
Florine M. Wiss, Samuel S. Allemann, Henriette E. Meyer zu Schwabedissen, Céline K. Stäuble, Thorsten Mikoteit, Markus L. Lampert
Publikováno v:
Frontiers in Psychiatry, Vol 15 (2024)
Suspected adverse drug reactions (ADRs) during treatment with clozapine often prompt therapeutic drug monitoring (TDM) in clinical practice. Currently, there is no official recommendation for pharmacogenetic (PGx) testing in the context of clozapine
Externí odkaz:
https://doaj.org/article/763b15bacd5e491ca34d86c7e9a7165f
Publikováno v:
Health Science Reports, Vol 7, Iss 1, Pp n/a-n/a (2024)
Abstract Background and Aims The World Health Organization has set a goal to eradicate hepatitis C virus (HCV) by the year 2030. Nonadherence to HCV treatment has substantial economic implications due to high treatment costs, among others. Barriers t
Externí odkaz:
https://doaj.org/article/2ee459531f204eb6a79ea66a64d69d49
Autor:
Carole Bandiera, Janette Ribaut, Alexandra L. Dima, Samuel S. Allemann, Kate Molesworth, Kabeza Kalumiya, Fabian Käser, Melvin Skip Olson, Michel Burnier, Job F. M. van Boven, Thomas Szucs, Daniel Albrecht, Ira Wilson, Sabina De Geest, Marie P. Schneider
Publikováno v:
International Journal of Public Health, Vol 67 (2022)
Externí odkaz:
https://doaj.org/article/ae15959ca68e4f068083dbfe823f12ce
Autor:
Céline K. Stäuble, Rebecca Meier, Markus L. Lampert, Thorsten Mikoteit, Martin Hatzinger, Samuel S. Allemann, Kurt E. Hersberger, Henriette E. Meyer zu Schwabedissen
Publikováno v:
Frontiers in Psychiatry, Vol 13 (2022)
We report the case of a 50-year-old male with major depressive disorder (MDD) to illustrate the challenge of finding effective antidepressant pharmacotherapy and the role that the patient’s genetic makeup may play. Recent treatment attempts before
Externí odkaz:
https://doaj.org/article/8c08dc3ac04b41ab97b7e314f52b0128
Autor:
Céline K. Stäuble, Chiara Jeiziner, Anna Bollinger, Florine M. Wiss, Martin Hatzinger, Kurt E. Hersberger, Thomas Ihde, Markus L. Lampert, Thorsten Mikoteit, Henriette E. Meyer zu Schwabedissen, Samuel S. Allemann
Publikováno v:
Pharmacy, Vol 10, Iss 4, p 86 (2022)
Genetic predisposition is one factor influencing interindividual drug response. Pharmacogenetic information can be used to guide the selection and dosing of certain drugs. However, the implementation of pharmacogenetics (PGx) in clinical practice rem
Externí odkaz:
https://doaj.org/article/07f761bc56374a8ab0b4a07076ec6e03
Autor:
Samuel S. Allemann, Kenneth M. Dürsteler, Johannes Strasser, Marc Vogel, Marcel Stoeckle, Kurt E. Hersberger, Isabelle Arnet
Publikováno v:
Harm Reduction Journal, Vol 14, Iss 1, Pp 1-8 (2017)
Abstract Background Patients with substance use disorders grow older thanks to effective treatments. Together with a high prevalence of comorbidities, psychological problems, and low social support, these patients are at high risk for medication non-
Externí odkaz:
https://doaj.org/article/7d4ab6fc487748f1ad30ce43f5ebb2f3
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2019)
Background: The description of adherence based on medication refill histories relies on the estimation of continuous medication availability (CMA) during an observation period. Thresholds to distinguish adherence from non-adherence typically refer to
Externí odkaz:
https://doaj.org/article/15e76db202774d8ca22d0057bee877d4
Publikováno v:
Epilepsia. 64:641-653
Medication adherence is considered an important risk factor for Sudden Unexpected Death in Epilepsy (SUDEP) although measurement accuracy is difficult. Using prescription dispensations, this study aims to estimate antiseizure medication (ASM) adheren
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ca6d5b30279f3e9ad38bf0047ca27a1
https://doi.org/10.1111/epi.17502
https://doi.org/10.1111/epi.17502